You are here

  • Home
  • Archive
  • Volume 10, Issue 9
  • Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity

Authors

  • Anqi Li College of Medicine, The Ohio State University, Columbus, Ohio, USAPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Yuzhou Chang Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USADepartment of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • No-Joon Song Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Xingjun Wu Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Dongjun Chung Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USADepartment of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Brian P Riesenberg Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Maria Velegraki Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Giuseppe D Giuliani Battelle Center for Mathematical Medicine, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USADepartment of Physics, The Ohio State University, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Komal Das Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Tamio Okimoto College of Medicine, The Ohio State University, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Hyunwoo Kwon College of Medicine, The Ohio State University, Columbus, Ohio, USAPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Karthik B Chakravarthy College of Medicine, The Ohio State University, Columbus, Ohio, USAPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Chelsea Bolyard Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Yi Wang Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Kai He Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USADivision of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Margaret Gatti-Mays Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USADivision of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Jayajit Das Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USADepartment of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Yiping Yang Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USADivision of Hematology, The Ohio State University College of Medicine, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Daniel T Gewirth Hauptman-Woodward Medical Research Institute, Buffalo, New York, USA PubMed articlesGoogle scholar articles
  • Qin Ma Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USADepartment of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • David Carbone Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USADivision of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Zihai Li Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USADivision of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Zihai Li; Zihai.Li{at}osumc.edu
View Full Text

Citation

Li A, Chang Y, Song N, et al
Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity
Journal for ImmunoTherapy of Cancer 2022;10:e005433. doi: 10.1136/jitc-2022-005433

Publication history

  • Accepted August 16, 2022
  • First published September 12, 2022.
Online issue publication 
September 12, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.